{"schema_version":"secwatch.filing_event.v1","accession":"0001023024-24-000055","form_type":"8-K","ticker":"ANIP","cik":"0001023024","company_name":"ANI PHARMACEUTICALS INC","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.924860+00:00","generated_at":"2026-06-02T03:11:12.910301+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ANI Pharmaceuticals Q1 2024: record revenue $137.4M, EPS $0.82; reiterates FY guidance","bullets":["Q1 net revenue $137.4M (+28.7% YoY); GAAP diluted EPS $0.82 vs $0.06; adjusted non-GAAP EPS $1.21.","Rare Disease segment (Cortrophin Gel) revenue $36.9M, up 126.2% YoY on higher volume.","Generics, Established Brands and Other segment revenue $100.5M, up 11.1% YoY; launched six new generics.","FY2024 guidance reaffirmed: revenue $520M-$542M; adjusted EBITDA $135M-$145M; adjusted EPS $4.26-$4.67.","Ended quarter with $228.6M cash; sold Oakville facility for $14.2M, recognized $9.7M gain on CG Oncology IPO."],"urls":{"canonical":"https://secwatch.observer/filing/0001023024-24-000055","json":"https://secwatch.observer/filing/0001023024-24-000055.json","markdown":"https://secwatch.observer/filing/0001023024-24-000055.md","text":"https://secwatch.observer/filing/0001023024-24-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1023024/000102302424000055/0001023024-24-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1023024/000102302424000055/ani-20240510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T03:11:12.910301+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"64ff645d66fd6a2d69ee38bf6955bbdc2ed4f938","claim":"ANI PHARMACEUTICALS INC reported the quarter ended March 31, 2024 results: revenue $137.4 million, net income $17.8 million, EPS $0.82. Guidance reaffirmed.","evidence_excerpt":"ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance • Generated record quarterly net revenues of $137.4 million, representing year-over-year growth of 28.7%, net income to common shareholders of $17.8 million, and GAAP diluted earnings per share of $0.82","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1023024/000102302424000055/0001023024-24-000055-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$137.4 million"},{"label":"Net income","value":"$17.8 million"},{"label":"EPS","value":"$0.82"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}